MGMT and central nervous system cancer: MGMT promoter methylation was associated with a superior OS in both TERT-mut (HR = 0.29; 95% CI = 0.21–0.39; I2 = 44%) and TERT-wt gliomas (HR = 0.54; 95% CI = 0.39–0.74; I2 = 19%).